Fresh analysis reveals that patients who stop using new weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Research printed in a leading medical journal demonstrates that while overweight people frequently drop substantial amounts of their body weight while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Users using these drugs need to be cognizant of the danger of rapid weight regain when the treatment concludes," warns researcher Dr. Susan Jebb.
This pace of recovery implies a return to starting mass within about a year and a half.
Comparing Therapies
The study, which examined dozens of trials involving thousands of patients, compared the effects of GLP-1 agonists with other pills.
Scientists emphasize that individuals who shed pounds through diet and exercise usually experience a more gradual creep back—approximately 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Doctors suggest the mode of action of the jabs is key to understanding the accelerated rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing the hormone levels several times higher than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication means appetite is uncontrolled, making excessive eating far more likely."
A Chronic Condition?
Medical guidelines recommend the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, considering the high risk of relapse, the therapy might need to be life-long.
This perspective is supported by pharmaceutical companies, who note that the findings "highlight the chronic nature of excess weight," comparing it to managing conditions like diabetes.
User Experiences
Users who have discontinued the medication explain a intense resurgence of hunger.
"I experienced a trigger flipping and I was suddenly extremely hungry," said one woman.
This challenge is exacerbated if patients have not adopted permanent dietary or behavioural changes during therapy.
Widespread Adoption
Recent estimates show that a significant number of people in the UK have used these injections in the past year, with interest being substantial.
- Adoption is more common among women than males.
- The middle-aged demographic shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
Finally, researchers caution that while the jabs are potent tools for shedding pounds, they are not a permanent fix and long-term success likely depends on ongoing behavioural support.
